跳到正文
原文
Nature Biotechnology·· 2026-10-12精选AI 评分70

FDA批准Revolution Medicines的RAS抑制剂Rasonque(daraxonrasib)用于转移性胰腺腺癌

RevMed’s pancreatic cancer drug first

AI 导读

美国FDA于8月批准Revolution Medicines的RAS抑制剂Rasonque(daraxonrasib)用于转移性胰腺腺癌,该药为靶向RAS的first-in-class药物。

推荐理由

该药作用于RAS的GTP结合态,与已上市的KRAS G12C抑制剂结合状态不同,可对比两类RAS靶向策略的差异。

正文
  • News in Brief
  • Published: 12 October 2026

Nature Biotechnology volume 44, page 1591 (2026) Cite this article

The US Food and Drug Administration (FDA) in August approved Revolution Medicines’ drug for the most common form of pancreatic cancer. The RAS inhibitor Rasonque (daraxonrasib) is a first-in-class drug targeting metastatic pancreatic adenocarcinoma. Shortly after, in September, an early-stage trial showed that the drug also has promise in lung cancer. These results bolster hopes that RAS inhibitors such as Rasonque could help combat a variety of hard-to-treat cancers such as pancreatic, lung and colorectal tumors.

Rasonque blocks multiple forms of the RAS protein — mutated KRAS and other RAS proteins present in over 90% of pancreatic tumors. Unlike traditional KRAS G12C- inhibitors like Lumakras (sotorasib) and Krazati (adagrasib), which bind the ‘off’ state of the protein, Rasonque binds the RAS GTPase in its GTP-bound ‘on’ conformation that drives oncogenic signaling. The drug works through a molecular glue mechanism, binding to both the abundant cellular protein cyclophilin A and RAS, preventing RAS from interacting with its signaling partners.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

27,99 € / 30 days

cancel any time

Subscription info for Chinese customers

We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

39,95 €

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

RevMed’s pancreatic cancer drug first. Nat Biotechnol 44, 1591 (2026). https://doi.org/10.1038/s41587-026-03363-2

Download citation

  • Published: 12 October 2026

  • Version of record: 12 October 2026

  • Issue date: October 2026

  • DOI: https://doi.org/10.1038/s41587-026-03363-2

来源:Nature Biotechnology · nature.com